Hosted on MSN1mon
MAIA’s lung cancer therapy 99% more likely to improve OS over chemo alone
A treatment for patients living with advanced non-small cell lung cancer (NSCLC ... sequenced in combination with Regeneron’s Libtayo (cemiplimab), a programmed cell death protein 1 (PD-1 ...
National Institute for Health and Care Excellence23d
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]
You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...
The American Journal of Managed Care3y
Recent Developments in the Treatment of Advanced Basal Cell Carcinoma
In February 2021, the ICI cemiplimab was approved by the FDA for use in patients with laBCC who have been previously treated with an HHI or for whom an HHI is not appropriate. 13,14 Prior to this ...
Business Wire29d
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab ... in Non-Small Cell Lung Cancer (NSCLC).
The Scientist2y
Bio-Rad Introduces Anti-Cemiplimab Antibodies
These ready-made antibodies are suitable for developing selective and sensitive assays for bioanalysis and drug monitoring of cemiplimab. Cemiplimab acts as a checkpoint inhibitor by binding to PD-1 ...
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...